A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of NGM/EE Tablets Manufactured at 2 Different Facilities
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2014
Price : $35 *
At a glance
- Drugs Ethinylestradiol/norgestimate (Primary)
- Indications Pregnancy
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 02 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Sep 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
- 29 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.